Skip to Content
Merck
All Photos(1)

Documents

59164

Supelco

SUPELCOSIL LC-18-DB (5 µm) HPLC Columns

L × I.D. 30 cm × 4 mm, HPLC Column

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501

product name

SUPELCOSIL LC-18-DB HPLC Column, 5 μm particle size, L × I.D. 30 cm × 4 mm

Agency

suitable for USP L1

Quality Level

feature

endcapped

manufacturer/tradename

SUPELCOSIL

extent of labeling

11.0% Carbon loading

parameter

0-70 °C temperature
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable

L × I.D.

30 cm × 4 mm

surface area

170 m2/g

surface coverage

surface coverage 3.1 μmol/m2

matrix

silica gel, spherical particle platform

matrix active group

C18 (octadecyl) phase

particle size

5 μm

pore size

120 Å

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

General description

SUPELCOSIL LC-DB phases are specially deactivated for basic compounds. These columns provide shorter retention, better peak shape, and higher efficiency for organic bases than can be obtained on other Type A silica reversed-phase columns.

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

SUPELCOSIL is a trademark of Sigma-Aldrich Co. LLC

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Carini et al.
Journal of pharmaceutical and biomedical analysis, 18(1-2), 201-211 (1998-12-24)
A study was undertaken for the characterization and quantitative determination of the main urinary metabolites of the non-steroidal anti-inflammatory drug (NSAID) nimesulide (4-nitro-2-phenoxy-methanesulfonanilide) in man following single oral administration (200 mg). Urines were collected from six healthy volunteers at 12
S L Bramer et al.
Journal of pharmaceutical and biomedical analysis, 26(4), 637-650 (2001-08-23)
An LC/MS/MS method for the simultaneous determination of cilostazol, a quinolinone derivative, and three active metabolites, OPC-13015, OPC-13213, and OPC-13217, in human plasma was developed and validated. Cilostazol, its metabolites, and the internal standard, OPC-3930 were extracted from human plasma
O Majid et al.
Therapeutic drug monitoring, 23(2), 163-168 (2001-04-11)
Recipients of organ transplants remain particularly dependent on prednisolone as part of their maintenance immunosuppression. Despite this, the pharmacokinetics of prednisolone have never been fully characterized in these patients, and consequently dosing remains empirical. Accurate monitoring of prednisolone, its primary
Vicky Manyanga et al.
Journal of pharmaceutical and biomedical analysis, 45(2), 257-262 (2007-08-21)
Several liquid chromatographic (LC) methods have been described for the analysis of gentamicin. LC combined with pulsed electrochemical detection (LC-PED) or evaporative light scattering detection (LC-ELSD) was found to be the most suitable technique. A first method, previously developed by
E Terjéki et al.
Journal of pharmaceutical and biomedical analysis, 24(5-6), 913-920 (2001-03-15)
RGH-1756 (1-(2-methoxy-phenyl)-4-(4-[4-(6-imidazo[2,1-b]-thiazolyl)-phenoxy]-butyl)-piperazine dimethansulphonate) is a novel atypical antipsychotic candidate of Gedeon Richter Ltd. A new HPLC method has been developed and validated for the quantitative determination of RGH-1756 in dog and rat plasma. The compound and the internal standard are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service